These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The path from scientific discovery to cures for epilepsy. Carvill GL; Dulla CG; Lowenstein DH; Brooks-Kayal AR Neuropharmacology; 2020 May; 167():107702. PubMed ID: 31301334 [TBL] [Abstract][Full Text] [Related]
3. Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening. Barker-Haliski M; Steve White H Neuropharmacology; 2020 May; 167():107750. PubMed ID: 31469995 [TBL] [Abstract][Full Text] [Related]
4. Making it personal: the prospects for autologous pluripotent stem cell-derived therapies. Blair NF; Barker RA Regen Med; 2016 Jul; 11(5):423-5. PubMed ID: 27346669 [No Abstract] [Full Text] [Related]
5. A new era of disease modeling and drug discovery using induced pluripotent stem cells. Suh W Arch Pharm Res; 2017 Jan; 40(1):1-12. PubMed ID: 27921262 [TBL] [Abstract][Full Text] [Related]
16. The use of induced pluripotent stem cells in drug development. Inoue H; Yamanaka S Clin Pharmacol Ther; 2011 May; 89(5):655-61. PubMed ID: 21430656 [TBL] [Abstract][Full Text] [Related]
17. Induced pluripotent stem cells (iPSCs) derived from different cell sources and their potential for regenerative and personalized medicine. Shtrichman R; Germanguz I; Itskovitz-Eldor J Curr Mol Med; 2013 Jun; 13(5):792-805. PubMed ID: 23642060 [TBL] [Abstract][Full Text] [Related]
18. Progress of Induced Pluripotent Stem Cell Technologies to Understand Genetic Epilepsy. Sterlini B; Fruscione F; Baldassari S; Benfenati F; Zara F; Corradi A Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940887 [TBL] [Abstract][Full Text] [Related]